109 related articles for article (PubMed ID: 15373969)
41. Targeted liposomal delivery of TLR9 ligands activates spontaneous antitumor immunity in an autochthonous cancer model.
Hamzah J; Altin JG; Herringson T; Parish CR; Hämmerling GJ; O'Donoghue H; Ganss R
J Immunol; 2009 Jul; 183(2):1091-8. PubMed ID: 19561111
[TBL] [Abstract][Full Text] [Related]
42. Immunology: DNA drives autoimmunity.
Vinuesa CG; Goodnow CC
Nature; 2002 Apr; 416(6881):595-8. PubMed ID: 11948338
[No Abstract] [Full Text] [Related]
43. Requirement for DNA CpG content in TLR9-dependent dendritic cell activation induced by DNA-containing immune complexes.
Yasuda K; Richez C; Uccellini MB; Richards RJ; Bonegio RG; Akira S; Monestier M; Corley RB; Viglianti GA; Marshak-Rothstein A; Rifkin IR
J Immunol; 2009 Sep; 183(5):3109-17. PubMed ID: 19648272
[TBL] [Abstract][Full Text] [Related]
44. Impact of nature and length of linker incorporated in agonists on toll-like receptor 9-mediated immune responses.
Putta MR; Yu D; Bhagat L; Wang D; Zhu FG; Kandimalla ER
J Med Chem; 2010 May; 53(9):3730-8. PubMed ID: 20361743
[TBL] [Abstract][Full Text] [Related]
45. Modulation of CpG oligodeoxynucleotide-mediated immune stimulation by locked nucleic acid (LNA).
Vollmer J; Jepsen JS; Uhlmann E; Schetter C; Jurk M; Wader T; Wüllner M; Krieg AM
Oligonucleotides; 2004; 14(1):23-31. PubMed ID: 15104893
[TBL] [Abstract][Full Text] [Related]
46. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE.
Tian J; Avalos AM; Mao SY; Chen B; Senthil K; Wu H; Parroche P; Drabic S; Golenbock D; Sirois C; Hua J; An LL; Audoly L; La Rosa G; Bierhaus A; Naworth P; Marshak-Rothstein A; Crow MK; Fitzgerald KA; Latz E; Kiener PA; Coyle AJ
Nat Immunol; 2007 May; 8(5):487-96. PubMed ID: 17417641
[TBL] [Abstract][Full Text] [Related]
47. Selectivity of Human TLR9 for Double CpG Motifs and Implications for the Recognition of Genomic DNA.
Pohar J; Yamamoto C; Fukui R; Cajnko MM; Miyake K; Jerala R; Benčina M
J Immunol; 2017 Mar; 198(5):2093-2104. PubMed ID: 28115525
[TBL] [Abstract][Full Text] [Related]
48. Immune complex negatively regulates Toll-like receptor 9-mediated immune responses in B cells through the inhibitory Fc-gamma receptor IIb.
Qian L; Chen W; Qin H; Rui C; Jia X; Fu Y; Gong W; Tian F; Ji M
Microbiol Immunol; 2015 Mar; 59(3):142-51. PubMed ID: 25557539
[TBL] [Abstract][Full Text] [Related]
49. Toll-like receptors and activation of autoreactive B cells.
Leadbetter EA; Rifkin IR; Marshak-Rothstein A
Curr Dir Autoimmun; 2003; 6():105-22. PubMed ID: 12408049
[No Abstract] [Full Text] [Related]
50. Regulation of CpG-induced immune activation by suppressive oligodeoxynucleotides.
Klinman DM; Zeuner R; Yamada H; Gursel M; Currie D; Gursel I
Ann N Y Acad Sci; 2003 Dec; 1002():112-23. PubMed ID: 14751829
[TBL] [Abstract][Full Text] [Related]
51. Short single-stranded DNA degradation products augment the activation of Toll-like receptor 9.
Pohar J; Lainšček D; Ivičak-Kocjan K; Cajnko MM; Jerala R; Benčina M
Nat Commun; 2017 May; 8():15363. PubMed ID: 28530246
[TBL] [Abstract][Full Text] [Related]
52. Differential signaling by CpG DNA in DCs and B cells: not just TLR9.
Verthelyi D; Zeuner RA
Trends Immunol; 2003 Oct; 24(10):519-22. PubMed ID: 14552833
[TBL] [Abstract][Full Text] [Related]
53. Phosphodiester backbone of the CpG motif within immunostimulatory oligodeoxynucleotides augments activation of Toll-like receptor 9.
Pohar J; Lainšček D; Kunšek A; Cajnko MM; Jerala R; Benčina M
Sci Rep; 2017 Nov; 7(1):14598. PubMed ID: 29097808
[TBL] [Abstract][Full Text] [Related]
54. RAGE-independent autoreactive B cell activation in response to chromatin and HMGB1/DNA immune complexes.
Avalos AM; Kiefer K; Tian J; Christensen S; Shlomchik M; Coyle AJ; Marshak-Rothstein A
Autoimmunity; 2010 Feb; 43(1):103-10. PubMed ID: 20014975
[TBL] [Abstract][Full Text] [Related]
55. Contribution of Toll-like receptor 9 signaling to the acute inflammatory response to nonviral vectors.
Zhao H; Hemmi H; Akira S; Cheng SH; Scheule RK; Yew NS
Mol Ther; 2004 Feb; 9(2):241-8. PubMed ID: 14759808
[TBL] [Abstract][Full Text] [Related]
56. Rheumatoid factor and immune complexes.
Devey ME; Hogben DN
Monogr Allergy; 1989; 26():230-9. PubMed ID: 2528062
[No Abstract] [Full Text] [Related]
57. Selective binding of anti-DNA antibodies to native dsDNA fragments of differing sequence.
Uccellini MB; Busto P; Debatis M; Marshak-Rothstein A; Viglianti GA
Immunol Lett; 2012 Mar; 143(1):85-91. PubMed ID: 22285306
[TBL] [Abstract][Full Text] [Related]
58. [Immune complex diseases in man and animal].
Trautwein G
Zentralbl Veterinarmed B; 1982 Apr; 29(3):165-85. PubMed ID: 6214126
[No Abstract] [Full Text] [Related]
59. [Current data on rheumatoid factors].
Youinou P; Le Goff P
Rev Rhum Ed Fr; 1994 Dec; 61(10 Pt 2):185S-193S. PubMed ID: 7532067
[TBL] [Abstract][Full Text] [Related]
60. The existence of insoluble-rheumatoid factor based immune complexes in menstrual fluid.
Halperin R; Hadas E; Bukovsky I; Schneider D
Immunol Invest; 2000 Nov; 29(4):365-72. PubMed ID: 11130779
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
